Glythera, an oncology spin-out of Bath University, has presented new data supporting the efficiency of its technology to fight cancer.
The spin-out’s PermaLink technology is able to address several issues currently faced by biotech companies wanting to exploit antibody drug conjugates. These conjugates are a new kind of drugs for targeted therapy, which blocks specific molecules responsible for tumour growth and metastasis. The other two available oncological treatments are hormonal therapy and chemotherapy.
PermaLink was recently granted a patent in the US.
Glythera was incorporated in 2008 through Bath’s technology transfer office Research and Innovation Services. It is based on research by Andrew Watts and Amanda Mackenzie at the Department of Pharmacy and Pharmacology.
Dave Simpson, chief executive at Glythera, said: “Glythera is confident of becoming a major player in the field of antibody-drug conjugates, an emerging class of biotherapeutics with market expectations for blockbuster potential. We believe that our PermaLink technology has the ideal attributes to become an important lynchpin in this growing field.”
